Transactions will fortify company’s U.S. presence.

WuXi PharmaTech plans to buy AppTec Laboratory Services in a deal valued at $151 million. The acquisition adds biologics capabilities to WuXi PharmaTech’s services. The firm will also gain a significant U.S. operational footprint.

It is expected that the combined business operations of WuXi PharmaTech and AppTec in the U.S. and China will enable WuXi PharmaTech to provide a full-service suite of outsourced chemistry and biology services to global pharmaceutical, biotechnology, and medical device clients.